Azilsartan is a highly potent and slowly dissociating Angiotensin II type 1 (AT1) receptor blocker (ARB) with an IC50 of 2.6 nM. It is the active form of Azilsartan medoxomil, used for treatment of hypertension. Azilsartan may also have potentially beneficial effects on metabolic syndrome including insulin sensitizing activity that may involve more than just blockade of AT(1) receptors.
Azilsartan is an Angiotensin II receptor blocker; anti-hypertensive.
To assess apolipoprotein L1 gene (APOL1) renal-risk-variant effects on the brain, magnetic resonance imaging (MRI)-based cerebral volumes and cognitive function were assessed in 517 African American-Diabetes Heart Study (AA-DHS) Memory IN Diabetes (MIND) and 2568 hypertensive African American Systolic Blood
Cardiovascular drugs and therapy, 33(5), 501-509 (2019-08-20)
Perivascular adipose tissues (PVAT) are involved in the regulation of vascular tone. In mesenteric arteries, the compensatory vasodilatory effects of PVAT appear when vascular relaxation is impaired and disappear at around 23 weeks of age in SHRSP.Z-Leprfa/IzmDmcr (SHRSP.ZF) rats with metabolic
Head and neck cancers (HNCs) cause significant mortality and morbidity. There have been few advances in therapeutic management of HNC in the past 4 to 5 decades, which support the need for studies focusing on HNC biology. In recent years
Hypertension research : official journal of the Japanese Society of Hypertension, 42(10), 1507-1517 (2019-05-30)
The sympathoinhibitory mechanism of azilsartan was investigated in an adenine-induced chronic renal failure model. Azilsartan exerted an antihypertensive effect, though BP elevation induced by adenine was marginal. The creatinine value was significantly lower in the azilsartan group (AZ) than in
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 28(5), 574-581 (2020-05-22)
Renin-angiotensin system exerted deleterious effects on learning and cognitive functions through different mechanisms. The present study has been designed to evaluate the protective effect of perindopril and azilsartan as monotherapy or in combination on aluminum chloride (AlCl3) induced neurobehavioral and
